BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36367044)

  • 21. Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases.
    Vajpayee N; Hussain J; Tolocica I; Hutchison RE; Gajra A
    J Neurooncol; 2010 Nov; 100(2):249-53. PubMed ID: 20446017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies?
    Royer-Perron L; Hoang-Xuan K; Alentorn A
    Curr Opin Neurol; 2017 Dec; 30(6):669-676. PubMed ID: 28922238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.
    Lin CH; Kuo KT; Chuang SS; Kuo SH; Chang JH; Chang KC; Hsu HC; Tien HF; Cheng AL
    Clin Cancer Res; 2006 Feb; 12(4):1152-6. PubMed ID: 16489068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment.
    Zhang Y; Zhou DB
    Chin Med J (Engl); 2020 Jun; 133(12):1462-1469. PubMed ID: 32452898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas.
    Fischer L; Hummel M; Korfel A; Lenze D; Joehrens K; Thiel E
    Neuro Oncol; 2011 Oct; 13(10):1090-8. PubMed ID: 21803762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors in primary central nervous system lymphoma.
    Morales-Martinez A; Nichelli L; Hernandez-Verdin I; Houillier C; Alentorn A; Hoang-Xuan K
    Curr Opin Oncol; 2022 Nov; 34(6):676-684. PubMed ID: 36093869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preferential up-regulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression.
    Yuan J; Gu K; He J; Sharma S
    Hum Pathol; 2013 Apr; 44(4):606-11. PubMed ID: 23089492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary central nervous system lymphoma.
    Schaff LR; Grommes C
    Blood; 2022 Sep; 140(9):971-979. PubMed ID: 34699590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testicular Relapse of Primary Diffuse Large B-cell Lymphoma of the Central Nervous System - a Rare Occurrence.
    Ollila TA; Kishkovich TP; Olszewski AJ; Patel NR; Jackson C; Roussel B; Niroula R; Treaba DO
    R I Med J (2013); 2023 Mar; 106(2):8-12. PubMed ID: 36848533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study.
    Labreche K; Daniau M; Sud A; Law PJ; Royer-Perron L; Holroyd A; Broderick P; Went M; Benazra M; Ahle G; Soubeyran P; Taillandier L; Chinot OL; Casasnovas O; Bay JO; Jardin F; Oberic L; Fabbro M; Damaj G; Brion A; Mokhtari K; Philippe C; Sanson M; Houillier C; Soussain C; Hoang-Xuan K; Houlston RS; Alentorn A;
    Neuro Oncol; 2019 Aug; 21(8):1039-1048. PubMed ID: 31102405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?
    Kim JA; Kim SJ; Do IG; Jin J; Nam DH; Ko YH; Kim K; Kim WS
    Leuk Lymphoma; 2011 Feb; 52(2):205-13. PubMed ID: 21281236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
    Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R
    Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary central nervous system lymphoma: Novel precision therapies.
    Mondello P; Mian M; Bertoni F
    Crit Rev Oncol Hematol; 2019 Sep; 141():139-145. PubMed ID: 31295667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathway analysis of primary central nervous system lymphoma.
    Tun HW; Personett D; Baskerville KA; Menke DM; Jaeckle KA; Kreinest P; Edenfield B; Zubair AC; O'Neill BP; Lai WR; Park PJ; McKinney M
    Blood; 2008 Mar; 111(6):3200-10. PubMed ID: 18184868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary treatment and recent survival trends in patients with primary diffuse large B-cell lymphoma of central nervous system, 1995-2016: A population-based SEER analysis.
    Chen C; Sun P; Sun XQ; Chen SY; Hang Yang ; Wang Y; Li ZM
    Hematol Oncol; 2023 Apr; 41(2):248-256. PubMed ID: 34472655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma.
    Lemma SA; Kuusisto M; Haapasaari KM; Sormunen R; Lehtinen T; Klaavuniemi T; Eray M; Jantunen E; Soini Y; Vasala K; Böhm J; Salokorpi N; Koivunen P; Karihtala P; Vuoristo J; Turpeenniemi-Hujanen T; Kuittinen O
    Carcinogenesis; 2017 Aug; 38(8):812-820. PubMed ID: 28854563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma.
    Sun X; Wang C; Chen C; Huang J; Wu X; Wang Y; He X; Cao J; Jiang W; Sun P; Li Z
    Hematol Oncol; 2021 Dec; 39(5):625-638. PubMed ID: 34543472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
    Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
    Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).
    Gomes Candido Reis D; Levy D; Lage LAPC; Culler HF; Rocha V; Bydlowski SP; Nogueira Zerbini MC; Pereira J
    Brain Behav; 2021 Apr; 11(4):e02061. PubMed ID: 33591648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.